Sonnet biotherapeutics provides fiscal year 2023 second quarter and year-to-date business and earnings update
Additional data presented from two clinical trials of son-1010 in both healthy volunteers and patients with advanced solid tumors. cytokine data reveal extended pk profile for son-1010: induces prolonged and controlled ifnΓ response no evidence of cytokine release syndrome clinical benefit was seen in 36% of patients (5/14) with advanced solid tumors entered into a collaboration with roche for the clinical evaluation of son-1010 with atezolizumab (tecentriq®) in ovarian cancer with study initiation currently underway announced data from two ind-enabling toxicology studies with son-1210 in non-human primates doses were well tolerated at over 50 times the anticipated human dose successfully completed a $15.0 million underwritten public offering princeton, nj / accesswire / may 10, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months and six months ended march 31, 2023 and provided a business update.
SONN Ratings Summary
SONN Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission